Amgen to Present New Autoimmune Disease Data at ACR 2026
Thousand Oaks, California, USA, October 27, 2026 Amgen has announced plans to present new clinical and real-world evidence across...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
Thousand Oaks, California, USA, October 27, 2026 Amgen has announced plans to present new clinical and real-world evidence across...
Thousand Oaks, California, U.S., September 22, 2026 Amgen has announced positive topline results from the pivotal Phase 3 OASIZ...
